A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Doxorubicin
Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma
Focus Therapeutic Use
Acronyms MEDISARC

04 Jun 2024 Results analyzing patient reported outcomes (PROs) under treatment.,presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Oct 2023 Results reporting efficacy and safety data presented at the 48th European Society for Medical Oncology Congress
24 Oct 2023 Primary endpoint has not been met. (overall survival (OS)) , according to Results presented at the 48th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com